American Vanguard (AVD) delivered a third quarter that weakened the 2026 story. The company lost $0.61 per share on revenue of $108.38 million. Revenue fell 9.2% year over year, and Earnings Whispers calculates a 238.9% year-over-year decline in earnings as the loss widened from $0.43 a year earlier. No consensus figure was available to frame a beat or miss. The more consequential news is that management cut full-year guidance for the first time after reaffirming it on three consecutive calls. Revenue guidance fell to $500-530 million from $530-550 million, and adjusted EBITDA guidance dropped to $36-40 million from $44-48 million. That cut is the central development of the quarter.

The composition of the loss looks worse than the headline. The year-ago quarter carried a $7.0 million product liability charge that did not recur. Even so, the operating loss widened to $8.0 million from $6.5 million. Gross margin fell to 24.2% from 28.7%, a steep drop from 31% in Q1 and 30% in Q2. Management attributes roughly 250 basis points of that decline to freight, with diesel up more than 40% in the quarter and more than 80% year to date, and says pricing is lagging. Adjusted EBITDA was essentially breakeven, down from $8.2 million a year ago, and it has slid sequentially from $10.3 million in Q1 and $6.6 million in Q2. Below the operating line, net interest expense nearly doubled to $9.1 million from $4.9 million following the company's refinancing.

The call showed that the deterioration has spread. International sales fell 17%, after declines of 7% in Q1 and 18% in Q2. The causes include El Niño in Central America, generic competition in Mexico, political uncertainty in Brazil, and copper-driven fungicide pricing. The U.S. business, which the CEO says continues to outperform peers, slipped 2% in both crop and specialty. Specialty had grown 11% in Q2, and nine-month U.S. growth of 3% now rests on first-half strength. Cost actions are real but small relative to these pressures. The Los Angeles plant closure is expected to save at least $4 million a year, and adjusted operating expenses fell $0.8 million to $27.8 million. Management's tone moved from Q1's 'time to play offense' to an acknowledgment that market conditions are doing the company no favors.

The revised outlook still asks a lot of the fourth quarter. The guidance implies Q4 sales of about $166 million, up roughly 10%, and EBITDA of about $21 million. That would exceed the $16.8 million generated across the first nine months combined. Management conceded that Q4 is not 'baked.' The balance sheet leaves little room for a shortfall. Gross leverage stands at 6.5x against a 6.7x first-lien covenant maximum. Total debt rose to about $268 million from $174 million at year-end after $225 million of term-loan borrowings, which carried $16.6 million of loan fees.

Cash did rise to $84 million, and net debt fell to $183.8 million from $224.7 million at Q2. Q3 customer prepayments jumped 44%, which the CFO said bodes well for the 2027 season. However, management expects Q4 prepayments of about $45 million versus roughly $55 million last year. That conflict tempers the prepayment signal, because Q4 is the larger prepay period.

The forward catalysts are genuine but longer-dated. At quarter-end, AVD acquired four U.S. brands and registrations from Syngenta for $9.5 million in total consideration. It also signed a specialty distribution agreement with Sipcam Agro, and together the two deals are expected to add $15-20 million of revenue. Other pipeline items include:

• the Duro LQ corn insecticide launching in Q4;
• ten product launches year to date;
• a Flute fungicide label extension in Australia.

These support management's goal of $100 million in annualized new-product revenue by 2030. Management also reiterated its 2028 targets of a revenue run-rate above $600 million and a double-digit EBITDA margin. Against those targets, investors must also weigh a U.S. farm economy leaning heavily on government aid and a CFO change that added $1.3 million in transition costs.

Current price and sentiment readings were not available. The last reference point, a $2.36 open after the August report, sat well below the current 200-day moving average of $2.79. The market was already treating the stock skeptically before this guidance cut.

The bottom line is that the third quarter turned AVD's transformation story from 'progress offset by tough markets' into a balance-sheet and execution question. Savings, prepayments and the Syngenta and Sipcam additions give bulls something to build on. However, margins are falling, international sales keep declining, guidance has been cut, and covenant headroom is thin. A heavily back-loaded Q4 now has to deliver before the longer-term product engine can matter.